Group 1 - The core viewpoint of the article is that Heng Rui Pharmaceutical is actively monitoring technological advancements in the industry and exploring their auxiliary applications in drug development [1] Group 2 - The company is engaging with investors through interactive platforms to address inquiries regarding its focus on technology [1]

证券日报网讯 2月11日，复星医药在互动平台回答投资者提问时表示，复宏汉霖是公司的控股子公司， 其收入全额纳入公司合并报表范围。创新药品收入方面，2025年公司前三季度创新药品收入超人民币67 亿元，较上年同期增长18.09%，并呈现稳健增长态势。随着2025年复迈宁、复妥宁、万缇乐、普瑞尼 等产品新获纳入国家医保目录以及奕凯达新获纳入商保创新药品目录，公司创新药品有望进一步扩大市 场覆盖、为收入提供增量。此外，公司创新管线临床开发的持续推进，也有望为后续年度公司创新药品 收入的增长提供新的动力。 （文章来源：证券日报） ...

Core Viewpoint - Anke Biopharma (300009.SZ) and its wholly-owned subsidiary Anhui Anke Hengyi Pharmaceutical Co., Ltd. have participated in the national centralized procurement for the continuation of products whose agreements have expired, with two of their products being included in the proposed selection list [1] Group 1 - Anke Biopharma and Anhui Anke Hengyi have submitted applications for the national centralized procurement for the continuation of products [1] - The proposed selection results for the continuation procurement were published by the procurement office on February 10, 2026 [1] - The products included in the proposed selection are Atosiban injection and oral formulation of Tenofovir disoproxil fumarate [1]

Core Viewpoint - Heng Rui Medicine emphasizes its commitment to technological innovation and international development strategies to ensure sustainable growth and better returns for shareholders [1] Group 1 - The company is actively pursuing a share buyback program as per its established plan [1]

Core Insights - The adjustment of China's medical insurance drug catalog for 2026 will focus on traditional Chinese medicines (TCM) with unclear contraindications, adverse reactions, and precautions in their instructions [1][2] - The principle of supporting innovation in medical insurance remains unchanged, with a dynamic adjustment approach that emphasizes the clinical value of innovations [1] - Drugs that have been clinically replaced, have uncertain clinical effects, or have not been produced for a long time will be prioritized for removal from the catalog [1] Group 1 - The National Medical Insurance Administration indicated that TCM with "unclear" items in their instructions may be removed from the insurance catalog [1] - The adjustment process will maintain a balance of adding and removing drugs, focusing on those that do not meet current clinical needs [1] - The recent regulations from the National Medical Products Administration state that any TCM with unclear contraindications, adverse reactions, or precautions will not be re-registered after July 1, 2026, potentially leading to a significant exit of TCM from the market [1] Group 2 - TCM applications for inclusion in the insurance catalog will face challenges if their instructions contain "unclear" items [2] - Existing TCM in the current catalog may also be removed if they have unresolved issues in their instructions, aligning with national safety and rational medication requirements [2]

Core Viewpoint - Jincheng Pharmaceutical announced that its subsidiaries participated in the national centralized procurement for expiring drug agreements, with seven products, including Cefoperazone Sodium Injection and Ceftazidime Injection, expected to be selected for procurement [1] Group 1: Company Performance - The total sales revenue of the seven products expected to be selected for procurement in the first three quarters of 2025 is projected to be 414.46 million yuan, accounting for 21.45% of the company's total revenue during the same period [1] Group 2: Procurement Details - The procurement results are expected to be implemented by the end of March 2026, with the procurement cycle lasting until December 31, 2028 [1] - Medical institutions will prioritize the use of the selected drugs during the procurement cycle, ensuring the completion of the agreed procurement volume [1]

Company News - Q Technology (01478.HK) reported a total sales volume of camera modules of 44.071 million units in January, representing a year-on-year increase of 22.8%. Fingerprint recognition module sales reached 19.741 million units, up 18.4% year-on-year, driven by increased overseas customer demand and a growing market share in the IoT and smart automotive sectors [2] - China Resources Power (00836.HK) achieved a sales volume of 23.78879 million megawatt-hours in January, a year-on-year increase of 28.4%. The sales from wind power plants increased by 7.2%, while solar power plant sales surged by 72.3% year-on-year [2] - NetEase-S (09999.HK) projected net revenue of approximately 112.626 billion yuan for 2025, a year-on-year growth of 6.96%, with net profit expected to be around 33.76 billion yuan, up 13.68% [2] - NetEase Cloud Music (09899.HK) anticipates revenue of about 7.759 billion yuan in 2025, with an expected profit of approximately 2.746 billion yuan, reflecting a significant year-on-year growth of 75.4%. The gross margin is expected to reach 35.7%, an increase from 33.7% in 2024, attributed to business scale growth, enhanced monetization capabilities, prudent cost management, and operational leverage [2] - Huitian Group (00806.HK) expects to achieve a consolidated profit attributable to shareholders of approximately 660 million HKD for the fiscal year 2025, a substantial increase from 31 million HKD in the previous year [2] Biotech Developments - Reborn Bio-B (06938.HK) entered into an exclusive global licensing agreement with Madrigal for several siRNA assets, receiving an upfront payment of 60 million USD, with potential cumulative payments of up to 4.4 billion USD upon achieving certain development, regulatory, and commercialization milestones, in addition to potential royalties on net sales [3] - Fuhong Hanlin (02696.HK) completed the first patient dosing in a Phase 1b/2 clinical study of HLX43 in combination with HLX07 or Hansizhuang® for patients with advanced or metastatic colorectal cancer in China [3] - Heng Rui Medicine (01276.HK) announced that its injection of Rukang Trastuzumab has been included in the list of breakthrough therapies, with global sales of similar products expected to reach approximately 6.557 billion USD in 2024 [3] - Saint Bella (02508.HK) made significant progress in its global strategic expansion plan, aiming to extend its reach to the eastern United States, the UK, France, Thailand, and Australia [3] - China National Biotech Group (08247.HK) signed a strategic cooperation agreement with Xiaoshou Medical to jointly promote the enhancement of quality medical resources and grassroots medical service capabilities [3] Buyback Activities - Geely Automobile (00175.HK) repurchased 1.201 million shares at a cost of 20.3042 million HKD, with repurchase prices ranging from 16.67 to 17.08 HKD [4] - Bairong Cloud-W (06608.HK) repurchased 1.66 million shares for 18.9051 million HKD, with share prices between 11.11 and 11.43 HKD [5] - Kingsoft (03888.HK) repurchased 355,200 shares at a cost of 9.9963 million HKD, with repurchase prices ranging from 27.9 HKD to 28.2 HKD [5]

Core Viewpoint - The company is focusing on high-end generic drugs while accelerating the development of improved new drugs, with a specific emphasis on the antifungal field through its self-developed project XT-0043, which has shown excellent safety and efficacy in Phase II clinical trials and is moving towards Phase III trials [2] Group 1 - The company is deeply engaged in the high-end generic drug market [2] - The first self-developed improved new drug project, XT-0043, is aimed at the antifungal area [2] - XT-0043 has demonstrated outstanding safety and efficacy in Phase II clinical trials and has successfully reached clinical endpoints [2] Group 2 - The company is currently focusing on advancing the Phase III clinical trial based on the data obtained from Phase II [2]

（文章来源：证券日报） 证券日报网讯 2月11日，恒瑞医药在互动平台回答投资者提问时表示，公司坚持差异化研发策略，以临 床需求为导向，利用领先的技术平台打造差异化创新产品矩阵。例如，公司自主研发的1类创新药瑞拉 芙普α注射液已于2026年1月在国内获批上市，是全球首款获批上市的抗PD-L1/TGF-βRII双特异性抗体 融合蛋白；公司还有100多个自主创新产品正在临床开发，其中不乏具有同类首创/同类最佳潜力的产 品。公司未来还将继续积极探索国际前沿的、具有同类首创或同类最佳潜力的药物靶点，不断产出差异 化、具有创新竞争力的产品。 ...

Core Viewpoint - Yiming Pharmaceutical (002826.SZ) announced a restricted stock incentive plan for 2026, aiming to enhance employee motivation and align their interests with shareholders [1] Group 1: Incentive Plan Details - The incentive plan proposes to grant a total of 3.4038 million restricted shares, which accounts for approximately 1.79% of the company's total share capital of 190.677750 million shares as of the announcement date [1] - A total of 26 individuals will be granted restricted shares under this plan, indicating a targeted approach to incentivizing key personnel [1] - The initial grant price for the restricted shares is set at 10.23 yuan per share, establishing a clear entry point for the incentive [1]